PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “BLADDER NEOPLASMS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1993

[Basic concepts in the use of tumor markers in the diagnosis and follow-up of malignant bladder neoplasms].

The absence of reliable diagnostic elements for the evaluation of malignant bladder tumors and the low sensitivity of the conventional diagnostic methods have prompted studies on the biological behaviour of this tumor type. The well known studies of Gold and Freedman and the recent investigations of Bates and Logo have proposed using tumor markers for early diagnosis and follow-up of different types of malignant tumors. However, the "ideal" tumor marker, one that is sufficiently sensitive and specific, has as yet to be discovered. We reviewed the tumor markers widely utilized to diagnose and follow-up malignant bladder tumors, and describe their main features. It must be pointed out that the lack of sensitivity and specificity of these tumor markers have led to the development of a new generation of tumor markers, such as cytogenetic markers, oncogenes, etc. Undoubtedly, this review of the literature will become obsolete with the advent of subsequent generations of tumor markers.

Biomarkers, Tumor↗
PubMed1996

[T1G3 bladder neoplasms: treatment and results].

The high risk of progression found in T1G3 bladder cancer influence the treatment and follow-up of this kind of patients. From January 1983 to December 1992, 803 patients with superficial bladder cancer (first presentation) had observed in the Urology Department at the Spedali Civili in Brescia. In this group, 96 patients were classified as T1G3 and our retrospective study is a critical analysis about their treatment: 13 patients underwent cystectomy as primary treatment and 83 had been cured with a transurethral resection. Of this last group, 26 patients are still without of disease (mean follow-up: 4.2 years), 30 had a recurrence which, in stage and grade, was identical or lower to the initial disease and 27 patients had a progression. Alltogether 36 patients underwent cystectomy: 15 are tumor-free and 21 died. The results of this retrospective study, led us to believe that T1G3 bladder cancer therapy is endoscopic at the beginning. Adjuvant topic chemotherapy treatments improve the recurrence rate tangibily; an early-operated cystectomy permits a good rate of recovery.

Carcinoma, Transitional Cell↗
PubMed1992

[Role of endovesical echography in the assessment of bladder neoplasms].

The correct assessment of T (depth of infiltration of bladder wall by cancer) is relevant to plan therapy. In fact, besides staging the local lesion, this can predict pelvic and lumboaortic lymphnode involvement (N parameter) statistically. At the INRCA Hospital in Florence, from January 1987 to December 1989, transurethral US was performed on 66 patients affected with bladder carcinomas, in order to assess the value of this diagnostic method; in all patients pathologic staging on surgical specimens from TUR (63 cases) and cystectomy (3 cases) was performed. Follow-up lasted 24 months at least. When comparing US staging (according to Holm classification) to postoperative histopathologic findings, our results showed that US tends to overstage the lesions, while no understaged tumors were seen in our series. Diagnostic accuracy was 70%. It must be pointed out that TRUS demonstrated hidden submucosal tumors in two patients previously treated with intravesical chemotherapy. Retrospectively, we were able to detect causes of error in cancer staging in some cases--i.e., large carcinomas, calcifications on tumors, radiotherapy scars, bladder wall inflammation due to intravesical BCG therapy. Moreover, some lesions which appeared to have been overstaged with TRUS and which had been treated according to histopathologic findings from TUR exhibited recurrence or disease progression. This was probably due to incomplete TUR and to the presence of residual tumor in the bladder wall.

Humans↗
PubMed1998

[Inflammatory type cutaneous metastasis of bladder neoplasm: erysipeloid carcinoma].

BACKGROUND: Skin metastasis from transitional cell carcinoma of the urinary bladder is quite uncommon. Especially, the inflammatory type of skin metastasis with features of carcinoma erysipeloid is a rare event. CASE REPORT: A 65-year-old man with bladder carcinoma who underwent radical cystectomy developed 6 months later red to violaceous papules, indurated plaques and edema in the perigenital area. The initial presumptive diagnosis was irritative contact dermatitis and cellulitis. Histologic examination of a skin biopsy disclosed dilated lymphatic vessels filled with neoplastic cells resembling transitional cells. COMMENT: Although carcinoma erypeloid is most commonly caused by breast carcinoma, it has also been linked to other carcinomas. Dermal lymphatic involvement is an essential feature shared by cases of inflammatory carcinoma. CONCLUSIONS: Carcinoma erysipeloid may be caused by bladder carcinoma. Skin metastases are generally present in the late stages of this disease and indicate a poor outcome.

Adenocarcinoma↗